You just read:

AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE® PD03A, Confirming Immunogenicity and Safety Profile in Parkinson's Disease Patients

News provided by

AFFiRiS AG

Jun 07, 2017, 11:00 ET